[go: up one dir, main page]

BR112016028749A2 - composto, forma cristalina, composição farmacêutica, e, método para o tratamento de uma doença. - Google Patents

composto, forma cristalina, composição farmacêutica, e, método para o tratamento de uma doença.

Info

Publication number
BR112016028749A2
BR112016028749A2 BR112016028749A BR112016028749A BR112016028749A2 BR 112016028749 A2 BR112016028749 A2 BR 112016028749A2 BR 112016028749 A BR112016028749 A BR 112016028749A BR 112016028749 A BR112016028749 A BR 112016028749A BR 112016028749 A2 BR112016028749 A2 BR 112016028749A2
Authority
BR
Brazil
Prior art keywords
disease
treating
compound
pharmaceutical composition
crystalline form
Prior art date
Application number
BR112016028749A
Other languages
English (en)
Inventor
Shi Bing
H Brown Brandon
Stefanidis Dimitrios
A Carra Ernest
Wang Fang
Morrison Henry
Andrew WHITNEY James
N Hemenway Jeffrey
Robert Warr Matthew
Reynolds Troy
Xin Yan
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53674249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016028749(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of BR112016028749A2 publication Critical patent/BR112016028749A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente invenção refere-se às novas formas de sal estáveis de n-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida que são adequadas para a preparação de formulações farmacêuticas das mesmas, e ao seu uso terapêutico.
BR112016028749A 2014-06-12 2015-06-11 composto, forma cristalina, composição farmacêutica, e, método para o tratamento de uma doença. BR112016028749A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462011315P 2014-06-12 2014-06-12
PCT/US2015/035316 WO2015191846A1 (en) 2014-06-12 2015-06-11 N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts

Publications (1)

Publication Number Publication Date
BR112016028749A2 true BR112016028749A2 (pt) 2017-08-22

Family

ID=53674249

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016028749A BR112016028749A2 (pt) 2014-06-12 2015-06-11 composto, forma cristalina, composição farmacêutica, e, método para o tratamento de uma doença.

Country Status (36)

Country Link
US (4) US9469613B2 (pt)
EP (3) EP3154950B1 (pt)
JP (5) JP6600649B2 (pt)
KR (1) KR101928225B1 (pt)
CN (2) CN106458929A (pt)
AP (1) AP2016009551A0 (pt)
AR (1) AR100818A1 (pt)
AU (1) AU2015274554B9 (pt)
BR (1) BR112016028749A2 (pt)
CA (1) CA2951883C (pt)
CR (1) CR20160575A (pt)
CU (1) CU20160183A7 (pt)
CY (2) CY1123604T1 (pt)
DK (1) DK3154950T3 (pt)
EA (1) EA032639B1 (pt)
EC (1) ECSP16093323A (pt)
ES (1) ES2822773T3 (pt)
FI (1) FIC20240025I1 (pt)
FR (1) FR24C1030I2 (pt)
HR (1) HRP20201492T1 (pt)
HU (2) HUE051360T2 (pt)
IL (3) IL249038B (pt)
LT (1) LT3154950T (pt)
MA (1) MA40067A (pt)
MX (3) MX374541B (pt)
NL (1) NL301282I2 (pt)
NZ (1) NZ725966A (pt)
PH (1) PH12016502461A1 (pt)
PL (1) PL3154950T3 (pt)
PT (1) PT3154950T (pt)
RS (1) RS61065B1 (pt)
SG (2) SG11201610079VA (pt)
SI (1) SI3154950T1 (pt)
TW (3) TW202134236A (pt)
UY (1) UY36166A (pt)
WO (1) WO2015191846A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202134236A (zh) 2014-06-12 2021-09-16 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN106316963B (zh) * 2015-06-26 2021-06-08 苏州泽璟生物制药股份有限公司 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物
CN106316964B (zh) * 2015-06-26 2019-06-25 苏州泽璟生物制药股份有限公司 苯基氨基嘧啶化合物或其盐的多晶型物
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018031579A1 (en) 2016-08-10 2018-02-15 Gilead Sciences, Inc. Momelotinib for treating of acvr1 -mediated diseases
EP3795157A4 (en) * 2018-05-15 2022-03-23 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. PHARMACEUTICAL COMPOSITION COMPRISING A SMALL MOLECULE EGFR INHIBITOR AND METHOD FOR PREPARING IT
SG11202100962XA (en) 2018-08-21 2021-03-30 Sierra Oncology Inc Platelet count-agnostic methods of treating myelofibrosis
WO2020167845A1 (en) * 2019-02-12 2020-08-20 Impact Biomedicines, Inc. Crystalline forms of a jak2 inhibitor
CA3227093A1 (en) 2021-07-30 2023-02-02 Bryan William STROUSE Biomarker and patient selection in treatment for myelofibrosis
CN117794546A (zh) 2021-08-10 2024-03-29 葛兰素史密斯克莱有限责任公司 莫洛替尼组合疗法
WO2023023473A1 (en) 2021-08-16 2023-02-23 Sierra Oncology, Inc. Methods of using momelotinib to treat chronic kidney disease
EP4413987A1 (en) * 2021-10-09 2024-08-14 Sunshine Lake Pharma Co., Ltd. Antifibrotic composition
WO2023152773A1 (en) * 2022-02-14 2023-08-17 Dr. Reddy's Institute Of Life Sciences Solid forms of momelotinib salts and improved processes for the preparation of momelotinib
CN119704552B (zh) * 2025-02-08 2025-06-13 泰州南洋塑料制品有限公司 一种电池槽注塑模具及边缘毛刺废料处理回收装置

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481932A (en) 1967-09-01 1969-12-02 Searle & Co 2-anilino-5-methyl-6-phenylpyrimidines and congeners
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US5559714A (en) 1990-10-22 1996-09-24 Hallmark Cards, Incorporated Method and apparatus for display sequencing personalized social occasion products
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
EP1363702A4 (en) 2001-01-30 2007-08-22 Cytopia Pty Ltd PROCESS FOR INHIBITING KINASES
MXPA03008888A (es) 2001-03-29 2005-03-07 Vertex Pharma Inhibidores de n-terminal c-jun cinasas (jnk) y otras proteinas cinasas.
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
EP1427391B1 (en) 2001-09-12 2008-07-09 ViRexx Medical Corporation Solid-phase agent for vascular occlusion with immobilised platelet binding agent
CN100558715C (zh) 2002-05-23 2009-11-11 西托匹亚有限公司 蛋白激酶抑制剂
US7304071B2 (en) 2002-08-14 2007-12-04 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP2172460A1 (en) 2002-11-01 2010-04-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
EP1562938B1 (en) 2002-11-04 2007-08-29 Vertex Pharmaceuticals Incorporated Heteroaryl-pyrimidine derivatives as jak inhibitors
JP2006508107A (ja) 2002-11-05 2006-03-09 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｊａｋおよび他のプロテインキナーゼのインヒビターとして有用な化合物
GB0317841D0 (en) 2003-07-30 2003-09-03 Cyclacel Ltd Compound
CA2533474A1 (en) 2003-07-30 2005-02-10 Shudong Wang 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
ME02688B (me) 2004-05-13 2017-10-20 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilinozitol 3 - kinaze delta
PE20060582A1 (es) 2004-10-13 2006-08-17 Wyeth Corp Analogos de anilino-pirimidina
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
EA200870217A1 (ru) 2006-01-30 2009-02-27 Экселиксис, Инк. 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
BRPI0708347A2 (pt) 2006-02-28 2011-05-24 Cytopia Res Pty Ltd inibição jak2 como um tratamento da hipertensão arterial pulmonar
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
AU2013201306B2 (en) 2007-03-12 2015-11-12 Glaxosmithkline Llc Phenyl Amino Pyrimidine Compounds and Uses Thereof
RS54533B1 (en) 2007-03-12 2016-06-30 Ym Biosciences Australia Pty Ltd PHENYL AMINOPYRIMIDINE COMPOUNDS AND THEIR APPLICATIONS
AU2016200866B2 (en) 2007-03-12 2017-06-22 Glaxosmithkline Llc Phenyl amino pyrimidine compounds and uses thereof
JP5611826B2 (ja) 2007-09-04 2014-10-22 ザ スクリプス リサーチ インスティテュート タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
WO2009073575A2 (en) 2007-11-30 2009-06-11 Oregon Health & Science University Methods for treating induced cellular proliferative disorders
BRPI0917575A2 (pt) 2008-08-05 2019-09-24 Targegen Inc métodos de tratamento de talassemia
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
US8580749B2 (en) 2009-06-05 2013-11-12 Cell Targeting, Inc. Peptide-coated cell localization to diseased or damaged tissues and methods related thereto
JP5086385B2 (ja) * 2010-03-08 2012-11-28 日立オートモティブシステムズ株式会社 電動パワーステアリング制御装置
PH12012502369A1 (en) 2010-05-31 2013-02-11 Ono Pharmaceutical Co Purinone derivative
CN104473933A (zh) * 2010-12-03 2015-04-01 Ym生物科学澳大利亚私人有限公司 Jak-2 介导的病症的治疗
MD20130089A2 (ro) * 2011-05-02 2014-05-31 Ym Biosciences Australia Pty Ltd Metodă de tratament al mielomului multiplu
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
JPWO2014051056A1 (ja) * 2012-09-28 2016-08-22 東レ株式会社 グリシン誘導体の結晶及びその医薬用途
ES2672468T3 (es) 2013-01-09 2018-06-14 Concert Pharmaceuticals Inc. Momelotinib deuterado
CN103965114B (zh) 2013-01-28 2016-01-06 苏州泽璟生物制药有限公司 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
TW202134236A (zh) * 2014-06-12 2021-09-16 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺

Also Published As

Publication number Publication date
LT3154950T (lt) 2020-11-25
MA40067A (fr) 2015-12-17
CY2024024I2 (el) 2025-03-28
AR100818A1 (es) 2016-11-02
MX2019009564A (es) 2019-10-02
CR20160575A (es) 2017-01-20
JP2021107465A (ja) 2021-07-29
TW202134236A (zh) 2021-09-16
IL276948B (en) 2021-09-30
MX374541B (es) 2025-03-06
NL301282I2 (nl) 2025-03-12
JP2017517535A (ja) 2017-06-29
MX2022015558A (es) 2023-01-30
PT3154950T (pt) 2020-10-09
ES2822773T3 (es) 2021-05-04
AU2015274554A1 (en) 2016-11-24
WO2015191846A1 (en) 2015-12-17
CN106458929A (zh) 2017-02-22
FR24C1030I1 (fr) 2024-08-30
DK3154950T3 (da) 2020-09-14
PL3154950T3 (pl) 2021-01-25
ECSP16093323A (es) 2017-01-31
SI3154950T1 (sl) 2021-01-29
US20160347719A1 (en) 2016-12-01
EA201692356A1 (ru) 2017-07-31
EA032639B1 (ru) 2019-06-28
EP3154950A1 (en) 2017-04-19
AP2016009551A0 (en) 2016-11-30
TW202012378A (zh) 2020-04-01
IL249038B (en) 2020-09-30
HUE051360T2 (hu) 2021-03-01
CU20160183A7 (es) 2017-05-10
CN110627728A (zh) 2019-12-31
CY1123604T1 (el) 2022-03-24
FIC20240025I1 (fi) 2024-07-12
MX2016016294A (es) 2017-09-01
SG11201610079VA (en) 2016-12-29
EP3154950B1 (en) 2020-08-05
NZ725966A (en) 2018-04-27
RS61065B1 (sr) 2020-12-31
KR20170015496A (ko) 2017-02-08
FR24C1030I2 (fr) 2025-06-13
JP7198867B2 (ja) 2023-01-04
TWI729644B (zh) 2021-06-01
JP2023021454A (ja) 2023-02-10
IL286442A (en) 2021-10-31
USRE49445E1 (en) 2023-03-07
US20150361050A1 (en) 2015-12-17
CA2951883C (en) 2020-05-05
HRP20201492T1 (hr) 2021-01-08
JP6840909B2 (ja) 2021-03-10
AU2015274554B9 (en) 2018-04-19
CA2951883A1 (en) 2015-12-17
JP6883560B2 (ja) 2021-06-09
JP2020059759A (ja) 2020-04-16
TWI681954B (zh) 2020-01-11
PH12016502461A1 (en) 2017-03-06
IL276948A (en) 2020-10-29
CY2024024I1 (el) 2025-03-28
JP6600649B2 (ja) 2019-10-30
UY36166A (es) 2016-01-29
AU2015274554B2 (en) 2018-02-15
HUS2400025I1 (hu) 2024-08-28
TW201617323A (zh) 2016-05-16
JP2018184486A (ja) 2018-11-22
US9469613B2 (en) 2016-10-18
KR101928225B1 (ko) 2018-12-11
USRE48285E1 (en) 2020-10-27
US9809559B2 (en) 2017-11-07
IL249038A0 (en) 2017-01-31
JP7550205B2 (ja) 2024-09-12
EP3719005A1 (en) 2020-10-07
SG10201911925TA (en) 2020-01-30
EP3907219A1 (en) 2021-11-10

Similar Documents

Publication Publication Date Title
BR112016028749A2 (pt) composto, forma cristalina, composição farmacêutica, e, método para o tratamento de uma doença.
CY1120673T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
MX382671B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
DOP2015000245A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
EA201691579A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201790892A1 (ru) Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
BR112016011065A8 (pt) composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia
ECSP13012770A (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
BR112017015852A2 (pt) forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
BR112017010402A2 (pt) carboxamida substituída à base de tiazol e oxazol e derivados de ureia como ligantes de receptor vanilóide ii
AR128459A2 (es) Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
CO2017003955A2 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
BR112017009471A2 (pt) síntese de copanlisib e seu sal de di-hidrocloreto.
EA201591684A1 (ru) Кристаллические формы ингибиторов тирозинкиназы и их солей
CY1123877T1 (el) Μορφες στερεας καταστασης αλατων νιλοτινιμπης
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
BR112017021631A2 (pt) composto, composição farmacêutica, combinação farmacêutica, método de tratamento, uso de um composto e processo para preparação de dito composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]